Overview

Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Atrial fibrillation (AF) is the most prevalent, sustained type of irregular heartbeat and affects over 2 million Americans. Post-operative AF, which leads to significant morbidity and a prolonged hospital stay, complicates 20% to 40% of cardiopulmonary bypass (CPB) surgical procedures. While recent studies indicate that interruption of the renin-angiotensin-aldosterone system by either angiotensin-converting enzyme (ACE) inhibition or AT1 receptor antagonism decreases the incidence of AF following a heart attack or cardioversion (electric shock to the heart), its effect on the incidence of post-operative AF has not been throughly studied. Studies in both animals and humans suggest that inflammation-induced atrial remodeling plays an important role in the cause of AF. Recent studies also provide evidence that activation of the renin-angiotensin-aldosterone system induces inflammation, myocyte injury, proarrhythmic electrical remodeling, and fibrosis through aldosterone.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Vanderbilt University
Vanderbilt University Medical Center
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Angiotensin-Converting Enzyme Inhibitors
Enzyme Inhibitors
Mineralocorticoid Receptor Antagonists
Mineralocorticoids
Ramipril
Spironolactone